Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 401–500 of 1,010
Loke, Y. K., Pradhan, S., Yeong, J. K.-Y., & Kwok, C. S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12376 · Cited by 63
Disadvantages of VKA and requirements for novel anticoagulants
Shameem, R., & Ansell, J. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.009 · Cited by 59
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population
von Vajna, E., Alam, R., & So, T.-Y. (2016) · Cardiology and Therapy · doi:10.1007/s40119-015-0054-y · Cited by 61
New oral anticoagulants: appropriateness of prescribing in real‐world setting
Pattullo, C., Barras, M. A., Tai, B., McKean, M., & Donovan, P. J. (2016) · Internal Medicine Journal · doi:10.1111/imj.13118 · Cited by 61
Caterina, R. D., & Lip, G. Y. H. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1102-5 · Cited by 57
“The EINSTEIN [37] and ROCKET AF [38] trials did not account for body weight or BMI in the exclusion criteria, In EINSTEIN, 14% of the participants weighed <100 kg, while ROCKET AF participants had an average BMI of 28 kg/m2.”
MethodInfluentialYamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2018) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872618799993 · Cited by 67
Timp, J. F., Brækkan, S. K., Lijfering, W. M., Vlieg, A. V. H., Hansen, J., Rosendaal, F. R., le Cessie, S., & Cannegieter, S. C. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002883 · Cited by 60
“Secondary prevention by means of continuation of the anticoagulant treatment will lead to reduction in the number of recurrent events [5].”
BackgroundBertoletti, L., Quenet, S., Laporte, S., Sahuquillo, J., Conget, F., Pedrajas, J., Martin, M., Casado, I., Riera-Mestre, A., Monreal, M., et al. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-75 · Cited by 56
Self-citationChatterjee, S., Sardar, P., Giri, J. S., Ghosh, J., & Mukherjee, D. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.030 · Cited by 59
Ndounga Diakou, L. A., Trinquart, L., Hróbjartsson, A., Barnes, C., Yavchitz, A., Ravaud, P., & Boutron, I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000043.pub2 · Cited by 58
Singer, A. J., Thode, H. C., & Peacock, W. F. (2016) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.15.096 · Cited by 63
Haas, S. K., Ageno, W., Angchaisuksiri, P., Bounameaux, H., Nielsen, J. D., Goldhaber, S. Z., Goto, S., Kayani, G., Mantovani, L. G., Prandoni, P., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-04-0335 · Cited by 65
Ovarian Vein Thrombosis: A Narrative Review
Riva, N., & Calleja‐Agius, J. (2020) · Hämostaseologie · doi:10.1055/a-1306-4327 · Cited by 63
Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus
Carrier, M., Blais, N., Crowther, M. A., Kavan, P., Gal, G. L., Moodley, O., Shivakumar, S., Suryanarayan, D., Tagalakis, V., Wu, C. M., et al. (2021) · Current Oncology · doi:10.3390/curroncol28060453 · Cited by 62
Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020
Iyer, G. S., Tesfaye, H., Khan, N. F., Zakoul, H., & Bykov, K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.4059 · Cited by 61
Beyer‐Westendorf, J., Gelbricht, V., Förster, K., Ebertz, F., Röllig, D., Schreier, T., Tittl, L., Thieme, C., Hänsel, U., Köhler, C. U., et al. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12391 · Cited by 56
Piazza, G. (2013) · JAMA · doi:10.1001/jama.2012.164493 · Cited by 60
Diretrizes Brasileiras de Antiagregantes Plaquetários e Anticoagulantes em Cardiologia
Filho, A. M. L., Azmus, A., Soeiro, A., Quadros, A., Avezum, Á., Marques, A., Franci, A., Manica, A., Volschan, A., de Paola, A., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s009 · Cited by 95
Harenberg, J., MARX, S., WEISS, C., Krämer, R., Samama, M. M., & Schulman, S. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04784.x · Cited by 54
Antithrombotic Management of Venous Thromboembolism
Renner, E., & Barnes, G. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.070 · Cited by 59
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Robertson, L., Kesteven, P. J., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub2 · Cited by 62
Mearns, E. S., Kohn, C. G., Song, J.-S., Hawthorne, J., Meng, J., White, C. M., Raut, M. K., Schein, J. R., & Coleman, C. I. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.035 · Cited by 61
Xu, X. S., Moore, K. T., Burton, P. B. J., Stuyckens, K., Mueck, W., Rossenu, S., Plotnikov, A. N., Gibson, C. M., & Vermeulen, A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04181.x · Cited by 56
Acute treatment of venous thromboembolism
Becattini, C., & Agnelli, G. (2020) · Blood · doi:10.1182/blood.2019001881 · Cited by 64
Marik, P. E., & Cavallazzi, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143252 · Cited by 53
Thom, K., Lensing, A. W. A., Nurmeev, I. N., Bajolle, F., Bonnet, D., Kenet, G., Massicotte, M. P., Karakaş, Z., Palumbo, J. S., Saracco, P., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002637 · Cited by 56
Vena cava filters for management of venous thromboembolism: A clinical review
Rajasekhar, A., & Streiff, M. B. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.07.001 · Cited by 58
“This conclusion may change with the emergence of new oral anticoagulants that appear at least as effective as warfarin in the treatment of VTE with potentially less bleeding [152–154].”
BackgroundBarco, S., Cheung, Y. W., Coppens, M., Hutten, B. A., Meijers, J. C. M., & Middeldorp, S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13821 · Cited by 58
New directions in the diagnosis and treatment of pulmonary embolism in pregnancy
Cutts, B. A., Dasgupta, D., & Hunt, B. J. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.06.035 · Cited by 53
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2012) · Journal of International Medical Research · doi:10.1177/030006051204000508 · Cited by 53
Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays
Lindhoff‐Last, E., Ansell, J., Spiro, T. E., & Samama, M. M. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.801274 · Cited by 53
Portal vein thrombosis: When to treat and how?
Sharma, A., Zhu, D., & Henry, Z. H. (2015) · Vascular Medicine · doi:10.1177/1358863x15611224 · Cited by 55
Direct oral anticoagulant considerations in solid organ transplantation: A review
Salerno, D. M., Tsapepas, D. S., Papachristos, A., Chang, J., Martin, S. T., Hardy, M. A., & McKeen, J. T. (2016) · Clinical Transplantation · doi:10.1111/ctr.12873 · Cited by 55
Goldhaber, S. Z., Schulman, S., Eriksson, H., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., Schellong, S., & Kakkar, A. K. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0176 · Cited by 58
Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors
Liu, M., Zaman, K., & Fortenberry, Y. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083897 · Cited by 54
Zhang, Z., Si, D., Zhang, Q., Jin, L., Zheng, H., Qu, M. F., Yu, M., Jiang, Z., Li, D., Li, S., et al. (2022) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.01.285 · Cited by 56
Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Brighton, T., Cohen, A. T., Davidson, B. L., Holberg, G., Kakkar, A. K., Lensing, A. W. A., Prins, M. H., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0131 · Cited by 55
“parenteral anticoagulant followed by a vitamin K antagonist) and is associated with fewer major bleeding events and improved treatment satisfaction [7-11].”
BackgroundSelf-citationWeinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 56
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15491 · Cited by 58
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 61
Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
Han, J., Luo, L., Wang, Y., Wu, S., & Kasim, V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.974775 · Cited by 55
“For medication treatment, drugs such as rivaroxaban and statins have been recently shown as potential drugs for treating ischemic diseases owing to their function as anti-platelet aggregation and anti-platelet thrombosis as well as for relaxing peripheral blood vessels and vasodilator (Investigators et al., 2010; Oest…”
BackgroundKaneda, K., Yamashita, Y., Morimoto, T., Chatani, R., Nishimoto, Y., Ikeda, N., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.08.007 · Cited by 58
Use of New Oral Anticoagulants in Antiphospholipid Syndrome
Arachchillage, D. J., & Cohen, H. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0331-5 · Cited by 55
Minno, M. N. D. D., Lupoli, R., Minno, A. D., Ambrosino, P., Scalera, A., & Dentali, F. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.982064 · Cited by 56
Aspirin for prevention and treatment of venous thromboembolism
Becattini, C., & Agnelli, G. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.03.003 · Cited by 53
“In the double blind EINSTEIN Extension study, 1197 patients who had completed 6 to 12 months of anticoagulant treatment for a first venous thromboembolism were randomized to receive an additional 6 or 12 months course of rivaroxaban (20 mg once daily; 602 patients) or placebo (594 patients) [54].”
BackgroundThe role of prothrombin complex concentrates in reversal of target specific anticoagulants
Babilonia, K., & Trujillo, T. C. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-8 · Cited by 52
“Rivaroxaban is also FDA approved for the prevention of venous thromboembolism (VTE) after orthopedic surgery, and very recently was approved for treatment of VTE [4].”
BackgroundMinimizing the Risk of Bleeding with NOACs in the Elderly
Kundu, A., Sardar, P., Chatterjee, S., Aronow, W. S., Owan, T., & Ryan, J. J. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0376-z · Cited by 58
“The EINSTEIN DVT [21] (patients with acute symptomatic DVT but no PE) and the EINSTEIN PE [22] (patients with symptomatic PE, with or without concomitant DVT) studies showed that rivaroxaban was noninferior to standard therapy with low-molecular-weight heparin (LMWH) followed by an adjusted-dose VKA for treatment of s…”
ResultRivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers
Levy, J. H., Moore, K. T., Neal, M. D., Schneider, D. J., Marcsisin, V. S., Ariyawansa, J., & Weitz, J. I. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13894 · Cited by 53
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
Stefano, V. D., Finazzi, G., & Barbui, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0101-8 · Cited by 58
Novel anticoagulants: general overview and practical considerations for dental practitioners
Elad, S., Marshall, J., Meyerowitz, C., & Connolly, G. (2015) · Oral Diseases · doi:10.1111/odi.12371 · Cited by 51
New Approaches to Inhibiting Platelets and Coagulation
Depta, J. P., & Bhatt, D. L. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124438 · Cited by 55
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban
Baglin, T. P. (2013) · British Journal of Haematology · doi:10.1111/bjh.12502 · Cited by 51
“…thrombosis (DVT) study, 3449 patients were randomized in an open label study to receive either rivaroxaban 20 mg daily (15 mg twice daily for the first 3 weeks), without a requirement for initial LMWH, or adjusted-dose warfarin to a target INR of 2 5 after initial LMWH (Bauersachs et al, 2010).”
BackgroundMethodInfluentialSubherwal, S., Patel, M. R., Chiswell, K., Tidemann-Miller, B. A., Jones, W. S., Conte, M. S., White, C. J., Bhatt, D. L., Laird, J. R., Hiatt, W. R., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.011021 · Cited by 50
Howard, M. E., Lipshutz, A. M., Roess, B., Hawes, E. M., Deyo, Z. M., Burkhart, J. I., Moll, S., & Shilliday, B. B. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1435-3 · Cited by 52
The use of direct oral anticoagulants in chronic kidney disease
Parker, K., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15564 · Cited by 53
Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists
Eerenberg, E. S., Middeldorp, S., Levi, M. M., Lensing, A. W. A., & Buller, H. R. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13051 · Cited by 50
Brunetti, N. D., Gesuete, E., Gennaro, L. D., Correale, M., Caldarola, P., Gaglione, A., & Biase, M. D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.168 · Cited by 54
Huang, H., Liu, P. P., Hsu, J., Lin, S., Peng, C. C., Wang, J., & Loh, C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz952 · Cited by 52
Chatterjee, S., Sharma, A., Uchino, K., Biondi‐Zoccai, G., Lichstein, E., & Mukherjee, D. (2013) · Coronary Artery Disease · doi:10.1097/mca.0000000000000031 · Cited by 54
The role of factor Xa inhibitors in venous thromboembolism treatment
Cabral, K. P., & Ansell, J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s39726 · Cited by 50
Harder, S. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-22 · Cited by 54
Sardar, P., Chatterjee, S., & Mukherjee, D. (2013) · Drugs · doi:10.1007/s40265-013-0082-7 · Cited by 50
“Newer agents dabigatran, rivaroxaban and apixaban have been evaluated recently in randomized trials for extended treatment of venous thromboembolism [9–11].”
BackgroundNew oral anticoagulants: which one should my patient use?
Weitz, J. I., & Gross, P. L. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.536.3798545 · Cited by 49
Recent advances in the management of pulmonary embolism: focus on the critically ill patients
Meyer, G., Vieillard‐Baron, A., & Planquette, B. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0122-z · Cited by 63
Drouet, L. O., Sollier, C. B. D., Steiner, T., & Purrucker, J. C. (2016) · International Journal of Stroke · doi:10.1177/1747493016659671 · Cited by 57
Edoxaban: A direct oral anticoagulant
Poulakos, M. N., Walker, J. N., Baig, U., & David, T. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150821 · Cited by 57
Direct acting oral anticoagulants for the treatment of suspected heparin‐induced thrombocytopenia
Davis, K., & Davis, D. O. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12921 · Cited by 50
Palareti, G., Antonucci, E., Mastroiacovo, D., Ageno, W., Pengo, V., Poli, D., Testa, S., Tosetto, A., & Prandoni, P. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14253 · Cited by 52
Wu, T., Lv, C., Wu, L., Chen, W., Lv, M., Jiang, S., & Zhang, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10448-2 · Cited by 54
Nitric oxide-driven nanomotors with bowl-shaped mesoporous silica for targeted thrombolysis
Tao, Y., Li, X., Wu, Z., Chen, C., Tan, K., Wan, M., Zhou, M., & Mao, C. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.12.065 · Cited by 48
Anticoagulation in chronic kidney disease: current status and future perspectives
Jones, A. P., Swan, D., Lisman, T., Barnes, G. D., & Thachil, J. V. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.020 · Cited by 62
Evaluation of the oral direct factor Xa inhibitor – betrixaban
Palladino, M. A., Merli, G. J., & Thomson, L. J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.825605 · Cited by 48
Management of venous thromboembolism: an update
Piran, S., & Schulman, S. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0107-z · Cited by 53
“All trials showed marked superiority of the DOACs over placebo for the prevention of recurrent VTE without significant increase in major bleeding [17,50, 51].”
BackgroundMethodResultInfluentialGodin, R., Marcoux, V., & Tagalakis, V. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.001 · Cited by 53
Milling, T. J., & Frontera, J. A. (2017) · PubMed · Cited by 63
Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome
Jeraj, L., Jezovnik, M. K., & Poredoš, P. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.029 · Cited by 48
Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis
Montiel, F. S., Ghazvinian, R., Gottsäter, A., & Elf, J. L. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0149-x · Cited by 52
Lutsey, P. L., Zakai, N. A., MacLehose, R. F., Norby, F. L., Walker, R. F., Roetker, N. S., Adam, T. J., & Alonso, A. (2019) · British Journal of Haematology · doi:10.1111/bjh.15857 · Cited by 47
Larsen, T. B., Skjøth, F., Kjældgaard, J. N., Lip, G. Y. H., Nielsen, P. B., & Søgaard, M. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30054-6 · Cited by 50
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants
Benamouzig, R., Guenoun, M., Deutsch, D., & Fauchier, L. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07211-0 · Cited by 58
Pharmacokinetics of rivaroxaban after bariatric surgery: a case report
Mahlmann, A., Gehrisch, S., & Beyer‐Westendorf, J. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0891-2 · Cited by 47
“However, in these trials, patients with morbid obesity were not specifically reported and only 15 % had a body weight [100 kg [9, 10].”
BackgroundLiew, A., Eikelboom, J. W., O'Donnell, M. J., & Hart, R. G. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.013 · Cited by 58
Trujillo, T. C., & Dobesh, P. P. (2014) · Drugs · doi:10.1007/s40265-014-0278-5 · Cited by 56
Pharmacology and mechanisms of action of new oral anticoagulants
Salem, J., Sabouret, P. F., Funck‐Brentano, C., & Hulot, J. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12091 · Cited by 51
He, Y., Wong, I. C. K., Li, X., Anand, S., Leung, W. K., Siu, C., & Chan, E. W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12911 · Cited by 51
Principles of Dielectric Blood Coagulometry as a Comprehensive Coagulation Test
Hayashi, Y., Brun, M.-A., Machida, K., & Nagasawa, M. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02723 · Cited by 47
Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome
Utne, K. K., Dahm, A. E. A., Wik, H. S., Jelsness‐Jørgensen, L., Sandset, P. M., & Ghanima, W. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.013 · Cited by 50
Weycker, D. A., Li, X., Wygant, G. D., Lee, T. T. H., Hamilton, M., Luo, X., Vo, L., Mardekian, J., Pan, X., Burns, L. C., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1673689 · Cited by 52
Jakowenko, N. D., Nguyen, S. N., Ruegger, M. C., Dinh, A., Salazar, E., & Donahue, K. R. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.09.002 · Cited by 48
Ko, D., Cove, C. L., & Hylek, E. M. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-12-1032 · Cited by 47
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
Thaler, J., Pabinger, I., & Ay, C. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00030 · Cited by 58
Burness, C. B., & Perry, C. M. (2014) · Drugs · doi:10.1007/s40265-013-0174-4 · Cited by 50
Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure
Raccah, B. H., Perlman, A., Danenberg, H. D., Pollak, A., Muszkat, M., & Matok, I. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.12.029 · Cited by 51
Platelets are key in cold physical plasma-facilitated blood coagulation in mice
Bekeschus, S., Brüggemeier, J., Hackbarth, C., von Woedtke, T., Partecke, L.-I., & van der Linde, J. (2017) · Clinical Plasma Medicine · doi:10.1016/j.cpme.2017.10.001 · Cited by 49
Sebastian, T., Hakki, L. O., Spirk, D., Baumann, F. A., Périard, D., Banyai, M., Spescha, R. S., Kucher, N., & Engelberger, R. P. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.10.027 · Cited by 46
Temporal Trends in the Practice Pattern for Venous Thromboembolism in Japan: Insight From JROAD‐DPC
Yamashita, Y., Morimoto, T., Yoshikawa, Y., Yaku, H., Sumita, Y., Nakai, M., Ono, K., & Kimura, T. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014582 · Cited by 51
Cheung, C., Parikh, J., Farrell, A., Lefebvre, M. J., Summa-Sorgini, C., & Battistella, M. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020967635 · Cited by 51
Cohen, A. T., Sah, J., Dhamane, A. D., Lee, T. T. H., Rosenblatt, L. C., Hlavacek, P., Emir, B., Delinger, R. L., Yüce, H., & Luo, X. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1740254 · Cited by 50
Kubitza, D., Berkowitz, S. D., & Misselwitz, F. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616631427 · Cited by 49
Peri-procedural management of patients taking oral anticoagulants
Daniels, P. R. (2015) · BMJ · doi:10.1136/bmj.h2391 · Cited by 47
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.